Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06144697 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 267
- Enrollment target
NCT06144697: Clinical Trial Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT06144697 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 267 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (345% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06144697, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 267 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.
Interventions
- OTHER Placebo
- DRUG Famotidine
- DRUG Pegasys
- DRUG BMS-986465
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2024-10-16 |
| Phase | Phase 1 |
Why NCT06144697 stopped before completion
NCT06144697 is an interventional study that assigns participants to a tested intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (345% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT06144697 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06144697 about?
NCT06144697 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants". The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.
What is the current status of trial NCT06144697?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 267 participants. The study started on 2024-01-29. Estimated completion is 2024-10-16.
What interventions are being tested in trial NCT06144697?
The interventions under investigation include: Placebo (OTHER), Famotidine (DRUG), Pegasys (DRUG), BMS-986465 (DRUG).
Who is sponsoring clinical trial NCT06144697?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06144697's enrollment target sits among peer trials
267 154th of 2000 higher than 1,847 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04997109 · 267 participants · NA
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
- NCT05355701 · 267 participants · Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- NCT06203509 · 267 participants · NA
Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI